Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK8 | P49336 | 1/20 | 1.00 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 6/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.77 |
| ▸ | HPGD | P15428 | 4/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.77 |
| ▸ | GAA | P10253 | 1/20 | 0.77 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.77 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.70 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | IKBKB | O14920 | 5/20 | 0.56 |
| ▸ | PIM1 | P11309 | 4/20 | 0.52 |
| ▸ | BRAF | P15056 | 2/20 | 0.49 |
| ▸ | PDE4A | P27815 | 2/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.49 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18849179 | 0.89 | CDK8 (0.80) | CDK8CDK19MAPTKDM4EHPGD | |
| SCHEMBL19769160 | 0.87 | CDK8 (0.77) | CDK8CDK19MAPTKDM4EHPGD | |
| SCHEMBL428537 | 0.87 | CDK8 (0.77) | CDK8CDK19MAPTKDM4EHPGD | |
| SCHEMBL430576 | 0.83 | LIMK1 (1.00) | CDK8CDK19MAPTKDM4EHPGD | |
| SCHEMBL19769229 | 0.82 | LIMK1 (0.82) | CDK8CDK19MAPTKDM4EHPGD | |
| SCHEMBL4657039 | 0.80 | CDK8 (0.67) | CDK8CDK19MAPTKDM4EHPGD | |
| SCHEMBL430610 | 0.79 | LIMK1 (0.74) | CDK8CDK19MAPTKDM4EHPGD | |
| SCHEMBL15347039 | 0.79 | MAPT (0.68) | CDK8CDK19MAPTKDM4EHPGD | |
| SCHEMBL12562468 | 0.75 | LIMK1 (0.72) | CDK8CDK19MAPTKDM4EHPGD | |
| SCHEMBL4900523 | 0.75 | MAPT (0.60) | CDK8CDK19MAPTKDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190111034-A1 | COMPOUNDS FOR TREATMENT OF HYPOPROLIFERATIVE DISORDERS | Apriligen, Inc. | 2019-04-18 | — | — | US | disclosed |
| US-20180015077-A1 | COMPOUNDS AND METHODS FOR TREATING HIV INFECTION | NAKAMURA, ROBERT | 2018-01-18 | — | — | US | disclosed |
| US-20180015077-A1 | COMPOUNDS AND METHODS FOR TREATING HIV INFECTION | NAKAMURA, ROBERT | 2018-01-18 | — | — | US | disclosed |
| EP-3181568-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | Siga Technologies, Inc. (US) | 2017-06-21 | — | — | EP | disclosed |
| EP-3181568-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | Siga Technologies, Inc. (US) | 2017-06-21 | — | — | EP | disclosed |
| WO-2017076968-A1 | COMPOUNDS FOR TREATMENT OF HYPOPROLIFERATIVE DISORDERS | LU LICENSE AB (SE) | 2017-05-11 | — | — | WO | disclosed |
| US-20170121344-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | SIGA TECHNOLOGIES, INC. (US) | 2017-05-04 | — | — | US | disclosed |
| US-20170121344-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | SIGA TECHNOLOGIES, INC. (US) | 2017-05-04 | — | — | US | disclosed |
| US-20170121344-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | SIGA TECHNOLOGIES, INC. (US) | 2017-05-04 | — | — | US | disclosed |
| EP-2400845-B1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | SIGA TECH INC (US) | 2017-02-22 | — | — | EP | disclosed |
| US-9301949-B2 | Thienopyridine derivatives for the treatment and prevention of dengue virus infections | SIGA TECHNOLOGIES, INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-9301949-B2 | Thienopyridine derivatives for the treatment and prevention of dengue virus infections | SIGA TECHNOLOGIES, INC. (US) | 2016-04-05 | — | — | US | disclosed |
| WO-2014089378-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | SIGA TECHNOLOGIES, INC. (US) | 2014-06-12 | — | — | WO | disclosed |
| US-20130129677-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | SIGA TECHNOLOGIES, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130129677-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | SIGA TECHNOLOGIES, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130129677-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | SIGA TECHNOLOGIES, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20120022046-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | SIGA TECHNOLOGIES, INC. | 2012-01-26 | — | — | US | disclosed |
| US-20120022046-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | SIGA TECHNOLOGIES, INC. | 2012-01-26 | — | — | US | disclosed |
| US-20120022046-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | SIGA TECHNOLOGIES, INC. | 2012-01-26 | — | — | US | disclosed |
| WO-2010099166-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | SIGA TECHNOLOGIES, INC. (US) | 2010-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022046-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | TTPA, TPMT, SLC19A2 | CDK8 2499/4885CDK19 4207/4885MAPT 138/4885 |
| US-20130129677-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | TTPA, TPMT, SLC19A2 | CDK8 2516/4885CDK19 4179/4885MAPT 85/4885 |
| US-20190111034-A1 | COMPOUNDS FOR TREATMENT OF HYPOPROLIFERATIVE DISORDERS | CDK9, CDK8, CDK18 | CDK8 2/4885CDK19 4/4885MAPT 3055/4885 |
| US-20170121344-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | TTPA, TPMT, SLC19A2 | CDK8 2516/4885CDK19 4179/4885MAPT 85/4885 |
| US-20180015077-A1 | COMPOUNDS AND METHODS FOR TREATING HIV INFECTION | CD4, CCR5, MMP8 | CDK8 1366/4885CDK19 3399/4885MAPT 1713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.